Nuvaira, Inc. is a privately held medical device company that develops therapies to improve outcomes for patients suffering from obstructive lung diseases by addressing underlying disease pathophysiology. Specifically, the company has developed a novel, catheter-based system to treat overactive airway nerves, a common disease underpinning of both COPD and asthma, in a procedure called Targeted Lung Denervation (TLD). The dNerva® lung denervation system is CE Mark approved. The dNerva® lung denervation system is under clinical investigation and is not commercially available in the USA. Nuvaira and dNerva are trademarks of Nuvaira, Inc.